Alembic Pharma Q2 PAT may dip 9.3% YoY to Rs. 110 cr: HDFC Securities

HDFC Securities has come out with its second quarter (July-September’ 18) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Alembic Pharma to report net profit at Rs. 110 crore down 9.3% year-on-year (up 21.9% quarter-on-quarter).

Net Sales are expected to increase by 18.8 percent Y-o-Y (up 8.7 percent Q-o-Q) to Rs. 940 crore, according to HDFC Securities.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 1.9 percent Y-o-Y (up 20.9 percent Q-o-Q) to Rs. 180 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.